For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome

Hello. We're improving abcam.com and we'd welcome your feedback.

Hello. We're improving abcam.com and we'd welcome your feedback.

Infomation icon

We haven't added this to the BETA yet

New BETA website

New BETA website

Hello. We're improving abcam.com and we'd welcome your feedback.

Take a look at our BETA site and see what we’ve done so far.

Switch on our new BETA site

Now available

Search and browse selected products

  • A selection of primary antibodies

Purchase these through your usual distributor

In the coming months

  • Additional product types
  • Supporting content
  • Sign in to your account
  • Purchase online
United States
Your country/region is currently set to:

If incorrect, please enter your country/region into the box below, to view site information related to your country/region.

Call (888) 77-ABCAM (22226) or contact us
Need help? Contact us

  • My account
  • Sign out
Sign in or Register with us

Welcome

Sign in or

Don't have an account?

Register with us
My basket
Quick order
Abcam homepage

  • Research Products
    By product type
    Primary antibodies
    Secondary antibodies
    ELISA and Matched Antibody Pair Kits
    Cell and tissue imaging tools
    Cellular and biochemical assays
    Proteins and Peptides
    By product type
    Proteomics tools
    Agonists, activators, antagonists and inhibitors
    Cell lines and Lysates
    Multiplex miRNA assays
    Multiplex Assays
    By research area
    Cancer
    Cardiovascular
    Cell Biology
    Epigenetics
    Metabolism
    Developmental Biology
    By research area
    Immunology
    Microbiology
    Neuroscience
    Signal Transduction
    Stem Cells
  • Customized Products & Partnerships
    Customized Products & Partnerships

    Customized products and commercial partnerships to accelerate your diagnostic and therapeutic programs.

    Customized products

    Partner with us

  • Support
    Support hub

    Access advice and support for any research roadblock

    View support hub

    Protocols

    Your experiments laid out step by step

    View protocols

  • Events
    • Conference calendar
    • Cancer
    • Cardiovascular
    • Epigenetics & Nuclear signaling
    • Immunology
    • Neuroscience
    • Stem cells
    • Tradeshows
    • Scientific webinars
    Keep up to date with the latest events

    Full event breakdown with abstracts, speakers, registration and more

    View global event calendar

  • Pathways
    Cell signalling pathways

    View all pathways

    View all interactive pathways

Explore the power of knock-out cell lines for your research

  1. Link

    fgfr3-phospho-y724-antibody-epr22813-ab155960.pdf

  1. Send me a copy of this email
    I agree to the terms and conditions.
Cardiovascular Angiogenesis Growth Factors FGF FGF Receptors
Share by email
RecombinantRabMAb

Recombinant Anti-FGFR3 (phospho Y724) antibody [EPR2281(3)] (ab155960)

  • Datasheet
  • SDS
Reviews (1)Q&A (1)References (10)

Product price, shipping and contact information

Currently unavailable

Sorry, we can't display this right now.

Please contact us to place your order, or try again later.

 

Loading size & price…

 

Shipping and order information

Shipping info

Promotion Information

Abpromise

Guaranteed product quality, expert customer support.

Find out more.

Western blot - Anti-FGFR3 (phospho Y724) antibody [EPR2281(3)] (ab155960)
  • Flow Cytometry (Intracellular) - Anti-FGFR3 (phospho Y724) antibody [EPR2281(3)] (ab155960)
  • Immunocytochemistry/ Immunofluorescence - Anti-FGFR3 (phospho Y724) antibody [EPR2281(3)] (ab155960)
  • Western blot - Anti-FGFR3 (phospho Y724) antibody [EPR2281(3)] (ab155960)
  • Dot Blot - Anti-FGFR3 (phospho Y724) antibody [EPR2281(3)] (ab155960)
  • Immunoprecipitation - Anti-FGFR3 (phospho Y724) antibody [EPR2281(3)] (ab155960)
  • Immunoprecipitation - Anti-FGFR3 (phospho Y724) antibody [EPR2281(3)] (ab155960)
  • Anti-FGFR3 (phospho Y724) antibody [EPR2281(3)] (ab155960)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [EPR2281(3)] to FGFR3 (phospho Y724)
  • Suitable for: Flow Cyt (Intra), Dot blot, WB, ICC/IF, IP
  • Reacts with: Human

Conjugates logo Related conjugates and formulations

Alexa Fluor® 488 Alexa Fluor® 647 Carrier Free

You may also be interested in

Cocktail
Product image
Membrane Fraction WB Cocktail (ab140365)
Biochemical
Product image
Harringtonine, translational protein synthesis inhibitor (ab141941)
Primary
Product image
Anti-FGFR1 (phospho Y653) antibody [EPR843(N)] (ab173305)

View more associated products

Overview

  • Product name

    Anti-FGFR3 (phospho Y724) antibody [EPR2281(3)]
    See all FGFR3 primary antibodies
  • Description

    Rabbit monoclonal [EPR2281(3)] to FGFR3 (phospho Y724)
  • Host species

    Rabbit
  • Tested applications

    Suitable for: Flow Cyt (Intra), Dot blot, WB, ICC/IF, IPmore details
    Unsuitable for: IHC-P
  • Species reactivity

    Reacts with: Human
    Predicted to work with: Mouse
  • Immunogen

    Synthetic peptide within Human FGFR3 (phospho Y724). The exact sequence is proprietary.
    Database link: P22607

  • Positive control

    • WB: MCF7 lysate treated with pervanadate. ICC/IF: MCF7 cells treated with pervanadate. IP: MCF7 cells treated with pervanadate. Flow Cyt (intra): MCF7 cells
  • General notes

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

    We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.

    Rat: We have preliminary internal testing data to indicate this antibody may not react with this species. Please contact us for more information.

Properties

  • Form

    Liquid
  • Storage instructions

    Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle.
  • Storage buffer

    Preservative: 0.01% Sodium azide
    Constituents: 40% Glycerol, 0.05% BSA, PBS
  • Concentration information loading...
  • Purity

    Protein A purified
  • Clonality

    Monoclonal
  • Clone number

    EPR2281(3)
  • Isotype

    IgG
  • Research areas

    • Cardiovascular
    • Angiogenesis
    • Growth Factors
    • FGF
    • FGF Receptors
    • Signal Transduction
    • Growth Factors/Hormones
    • FGF
    • Cancer
    • Growth factors
    • FGF
    • Stem Cells
    • Neural Stem Cells
    • Glial Restricted Lineage
    • Astrocyte
    • Neuroscience
    • Development
    • Neuroscience
    • Processes

Associated products

  • Alternative Versions

    • Anti-FGFR3 (phospho Y724) antibody [EPR2281(3)] - Low endotoxin, Azide free (ab215385)
    • Alexa Fluor® 488 Anti-FGFR3 (phospho Y724) antibody [EPR2281(3)] (ab237164)
    • Alexa Fluor® 647 Anti-FGFR3 (phospho Y724) antibody [EPR2281(3)] (ab237165)
    • Anti-FGFR3 (phospho Y724) antibody [EPR2281(3)] - BSA and Azide free (ab271918)
  • Compatible Secondaries

    • Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077)
    • Goat Anti-Rabbit IgG H&L (HRP) (ab205718)
  • Conjugation kits

    • PE / R-Phycoerythrin Conjugation Kit - Lightning-Link® (ab102918)
    • APC Conjugation Kit - Lightning-Link® (ab201807)
  • Isotype control

    • Rabbit IgG, monoclonal [EPR25A] - Isotype Control (ab172730)
  • Recombinant Protein

    • Recombinant human FGFR3 protein (ab60857)

Applications

The Abpromise guarantee

Our Abpromise guarantee covers the use of ab155960 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Flow Cyt (Intra)
1/50.
Dot blot
1/1000.
WB (1)
1/1000 - 1/10000. Predicted molecular weight: 88 kDa.

 

ICC/IF
1/80 - 1/300.

 

IP
1/15 - 1/50.

 

Notes
Flow Cyt (Intra)
1/50.
Dot blot
1/1000.
WB
1/1000 - 1/10000. Predicted molecular weight: 88 kDa.

 

ICC/IF
1/80 - 1/300.

 

IP
1/15 - 1/50.

 

Application notes
Is unsuitable for IHC-P.

Target

  • Function

    Receptor for acidic and basic fibroblast growth factors. Preferentially binds FGF1.
  • Tissue specificity

    Expressed in brain, kidney and testis. Very low or no expression in spleen, heart, and muscle. In 20- to 22-week old fetuses it is expressed at high level in kidney, lung, small intestine and brain, and to a lower degree in spleen, liver, and muscle. Isoform 2 is detected in epithelial cells. Isoform 1 is not detected in epithelial cells. Isoform 1 and isoform 2 are detected in fibroblastic cells.
  • Involvement in disease

    Defects in FGFR3 are the cause of achondroplasia (ACH) [MIM:100800]. ACH is an autosomal dominant disease and is the most frequent form of short-limb dwarfism. It is characterized by a long, narrow trunk, short extremities, particularly in the proximal (rhizomelic) segments, a large head with frontal bossing, hypoplasia of the midface and a trident configuration of the hands.
    Defects in FGFR3 are the cause of Crouzon syndrome with acanthosis nigricans (CAN) [MIM:612247]. Classic Crouzon disease which is caused by mutations in the FGFR2 gene is characterized by craniosynostosis (premature fusion of the skull sutures), and facial hypoplasia. Crouzon syndrome with acanthosis nigricans (a skin disorder characterized by pigmentation anomalies), CAN, is considered to be an independent disorder from classic Crouzon syndrome. CAN is characterized by additional more severe physical manifestation, such as Chiari malformation, hydrocephalus, and atresia or stenosis of the choanas, and is caused by a specific mutation (Ala-391 to Glu) in the transmembrane domain of FGFR3. It is proposed to have an autosomal dominant mode of inheritance.
    Defects in FGFR3 are a cause of thanatophoric dysplasia type (TD) [MIM:187600, 187601]; also known as thanatophoric dwarfism or platyspondylic lethal skeletal dysplasia Sand Diego type (PLSD-SD). TD is the most common neonatal lethal skeletal dysplasia. Affected individuals display features similar to those seen in homozygous achondroplasia. It causes severe shortening of the limbs with macrocephaly, narrow thorax and short ribs. In the most common subtype, TD1, femur are curved, while in TD2, straight femurs are associated with cloverleaf skull. Mutations affecting different functional domains of FGFR3 cause different forms of this lethal disorder.
    Defects in FGFR3 are a cause of hypochondroplasia (HCH) [MIM:146000]. HCH is an autosomal dominant disease and is characterized by disproportionate short stature. It resembles achondroplasia, but with a less severe phenotype.
    Defects in FGFR3 are a cause of susceptibility to bladder cancer (BLC) [MIM:109800]. A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas. They begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences. Note=Somatic mutations can constitutively activate FGFR3.
    Defects in FGFR3 are a cause of cervical cancer (CERCA) [MIM:603956]. A malignant neoplasm of the cervix, typically originating from a dysplastic or premalignant lesion previously present at the active squamocolumnar junction. The transformation from mild dysplastic to invasive carcinoma generally occurs slowly within several years, although the rate of this process varies widely. Carcinoma in situ is particularly known to precede invasive cervical cancer in most cases. Cervical cancer is strongly associated with infection by oncogenic types of human papillomavirus.
    Defects in FGFR3 are the cause of camptodactyly tall stature and hearing loss syndrome (CATSHL syndrome) [MIM:610474]. CATSHL syndrome is an autosomal dominant syndrome characterized by permanent and irreducible flexion of one or more fingers of the hand and/or feet, tall stature, scoliosis and/or a pectus excavatum, and hearing loss. Affected individuals have developmental delay and/or mental retardation, and several of these have microcephaly. Radiographic findings included tall vertebral bodies with irregular borders and broad femoral metaphyses with long tubular shafts. On audiological exam, each tested member have bilateral sensorineural hearing loss and absent otoacoustic emissions. The hearing loss was congenital or developed in early infancy, progressed variably in early childhood, and range from mild to severe. Computed tomography and magnetic resonance imaging reveal that the brain, middle ear, and inner ear are structurally normal.
    Defects in FGFR3 are a cause of multiple myeloma (MM) [MIM:254500]. MM is a malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. Note=A chromosomal aberration involving FGFR3 is found in multiple myeloma. Translocation t(4;14)(p16.3;q32.3) with the IgH locus.
    Defects in FGFR3 are a cause of lacrimo-auriculo-dento-digital syndrome (LADDS) [MIM:149730]; also known as Levy-Hollister syndrome. LADDS is a form of ectodermal dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. LADDS is an autosomal dominant syndrome characterized by aplastic/hypoplastic lacrimal and salivary glands and ducts, cup-shaped ears, hearing loss, hypodontia and enamel hypoplasia, and distal limb segments anomalies. In addition to these cardinal features, facial dysmorphism, malformations of the kidney and respiratory system and abnormal genitalia have been reported. Craniosynostosis and severe syndactyly are not observed.
    Defects in FGFR3 are a cause of keratinocytic non-epidermolytic nevus (KNEN) [MIM:162900]; also known as pigmented moles. Epidermal nevi of the common, non-organoid and non-epidermolytic type are benign skin lesions and may vary in their extent from a single (usually linear) lesion to widespread and systematized involvement. They may be present at birth or develop early during childhood.
    Defects in FGFR3 are a cause of Muenke syndrome (MNKS) [MIM:602849]; also known as Muenke non-syndromic coronal craniosynostosis. MNKS is a condition characterized by premature closure of coronal suture of skull during development (coronal craniosynostosis), which affects the shape of the head and face. It may be uni- or bilateral. When bilateral, it is characterized by a skull with a small antero-posterior diameter (brachycephaly), often with a decrease in the depth of the orbits and hypoplasia of the maxillae. Unilateral closure of the coronal sutures leads to flattening of the orbit on the involved side (plagiocephaly). The intellect is normal. In addition to coronal craniosynostosis some affected individuals show skeletal abnormalities of hands and feet, sensorineural hearing loss, mental retardation and respiratory insufficiency.
    Defects in FGFR3 are a cause of keratosis seborrheic (KERSEB) [MIM:182000]. A common benign skin tumor. Seborrheic keratoses usually begin with the appearance of one or more sharply defined, light brown, flat macules. The lesions may be sparse or numerous. As they initially grow, they develop a velvety to finely verrucous surface, followed by an uneven warty surface with multiple plugged follicles and a dull or lackluster appearance.
  • Sequence similarities

    Belongs to the protein kinase superfamily. Tyr protein kinase family. Fibroblast growth factor receptor subfamily.
    Contains 3 Ig-like C2-type (immunoglobulin-like) domains.
    Contains 1 protein kinase domain.
  • Cellular localization

    Membrane.
  • Target information above from: UniProt accession P22607 The UniProt Consortium
    The Universal Protein Resource (UniProt) in 2010
    Nucleic Acids Res. 38:D142-D148 (2010) .

    Information by UniProt
  • Database links

    • Entrez Gene: 2261 Human
    • Entrez Gene: 14184 Mouse
    • Omim: 134934 Human
    • SwissProt: P22607 Human
    • SwissProt: Q61851 Mouse
    • Unigene: 1420 Human
    • Unigene: 6904 Mouse
    • Alternative names

      • ACH antibody
      • CD 333 antibody
      • CD333 antibody
      • CD333 antigen antibody
      • CEK 2 antibody
      • CEK2 antibody
      • FGFR 3 antibody
      • FGFR-3 antibody
      • FGFR3 antibody
      • FGFR3_HUMAN antibody
      • Fibroblast growth factor receptor 3 (achondroplasia thanatophoric dwarfism) antibody
      • Fibroblast growth factor receptor 3 antibody
      • Heparin binding growth factor receptor antibody
      • HSFGFR3EX antibody
      • Hydroxyaryl protein kinase antibody
      • JTK 4 antibody
      • JTK4 antibody
      • MFR 3 antibody
      • SAM 3 antibody
      • Tyrosine kinase JTK 4 antibody
      • Tyrosine kinase JTK4 antibody
      • Z FGFR 3 antibody
      see all

    Images

    • Western blot - Anti-FGFR3 (phospho Y724) antibody [EPR2281(3)] (ab155960)
      Western blot - Anti-FGFR3 (phospho Y724) antibody [EPR2281(3)] (ab155960)
      All lanes : Anti-FGFR3 (phospho Y724) antibody [EPR2281(3)] (ab155960) at 1/20000 dilution (purified)

      Lane 1 : MCF7 cell lysate - untreated
      Lane 2 : MCF7 cell lysate - treated with pervanadate

      Lysates/proteins at 10 µg per lane.

      Secondary
      All lanes : Peroxidase-conjugated goat anti-rabbit IgG (H+L) at 1/1000 dilution

      Predicted band size: 88 kDa
      Observed band size: 96 kDa why is the actual band size different from the predicted?



      Blocking and dilution buffer: 5% NFDM/TBST.

    • Flow Cytometry (Intracellular) - Anti-FGFR3 (phospho Y724) antibody [EPR2281(3)] (ab155960)
      Flow Cytometry (Intracellular) - Anti-FGFR3 (phospho Y724) antibody [EPR2281(3)] (ab155960)

      Intracellular Flow Cytometry analysis of MCF7 (human breast carcinoma) treated with 1 mM pervanadate for 30 minutes cells labeling FGFR3 (phospho Y724) with purified ab155960 at 1/50 dilution (red). The secondary antibody was Goat anti rabbit IgG (Alexa Fluor® 488) at 1/2000 dilution. Green shows untreated MCF7 (human breast carcinoma) cells. A Rabbit monoclonal IgG (Black) was used as the isotype control and cells without incubation with primary antibody and secondary antibody (Blue) were used as unlabeled control. 

       

       

    • Immunocytochemistry/ Immunofluorescence - Anti-FGFR3 (phospho Y724) antibody [EPR2281(3)] (ab155960)
      Immunocytochemistry/ Immunofluorescence - Anti-FGFR3 (phospho Y724) antibody [EPR2281(3)] (ab155960)

      Immunocytochemistry/Immunofluorescence analysis of untreated, Per treated and Per + LP treated MCF7 cells labelling FGFR3 (phospho Y724) with ab155960 (left) and FGFR3 with ab137084 (right) both at a dilution of 1/200.

      Cells were fixed with 100% methanol. ab150077, an Alexa Fluor® 488-conjugated goat anti-rabbit IgG (1/1000) was used as the secondary antibody. DAPI (blue) was used as the nuclear counterstain. ab7291, a mouse anti-tubulin (1/1000) and ab150120, an Alexa Fluor® 594-conjugated goat anti-mouse IgG (1/1000) were also used.

      The image shows increased cytoplasmic staining after Pervanadate (1 mM, 30 min) treatment on MCF7 cells. The LP treatment decreased the cytoplasmic staining caused by Pervanadate.

      ab137084 was used as a Pan control for ab155960. The results showed cytoplasmic staining on untreated, Per treated and Per + LP treated MCF7 cells.

    • Western blot - Anti-FGFR3 (phospho Y724) antibody [EPR2281(3)] (ab155960)
      Western blot - Anti-FGFR3 (phospho Y724) antibody [EPR2281(3)] (ab155960)
      All lanes : Anti-FGFR3 (phospho Y724) antibody [EPR2281(3)] (ab155960) at 1/10000 dilution (unpurified)

      Lane 1 : MCF7 whole cell lysate - treated with pervanadate
      Lane 2 : MCF7 whole cell lysate - untreated

      Lysates/proteins at 10 µg per lane.

      Secondary
      All lanes : Peroxidase-conjugated goat anti-rabbit IgG (H+L) at 1/1000 dilution

      Predicted band size: 88 kDa
      Observed band size: 98 kDa why is the actual band size different from the predicted?


      Exposure time: 30 seconds


      Blocking and dilution buffer: 5% NFDM/TBST.

    • Dot Blot - Anti-FGFR3 (phospho Y724) antibody [EPR2281(3)] (ab155960)
      Dot Blot - Anti-FGFR3 (phospho Y724) antibody [EPR2281(3)] (ab155960)

      Dot blot analysis of human FGFR3 (pY724) phospho peptide (lane 1) and human FGFR3 non-phospho peptide (lane 2) labelling FGFR2 (phospho Y724) with ab155960 at a dilution of 1/1000. A peroxidase-conjugated goat anti-rabbit IgG (H+L) was used as the secondary antibody (1/2500).

      Blocking and dilution buffer: 5% NFDM/TBST.

      Exposure time: 10 seconds.

    • Immunoprecipitation - Anti-FGFR3 (phospho Y724) antibody [EPR2281(3)] (ab155960)
      Immunoprecipitation - Anti-FGFR3 (phospho Y724) antibody [EPR2281(3)] (ab155960)

      ab155960 (unpurified) at 1/15 immunoprecipitating FGFR3 (phospho Y724) in MCF7 cells treated with pervanadate. For western blotting, a peroxidase-conjugated goat anti-rabbit IgG (H+L) was used as the secondary antibody (1/1000).

      Blocking buffer and concentration: 5% NFDM/TBST.

      Diluting buffer and concentration: 5% NFDM /TBST.

    • Immunoprecipitation - Anti-FGFR3 (phospho Y724) antibody [EPR2281(3)] (ab155960)
      Immunoprecipitation - Anti-FGFR3 (phospho Y724) antibody [EPR2281(3)] (ab155960)

      ab155960 (purified) at 1/50 immunoprecipitating FGFR3 (phospho Y724) in MCF7 cells treated with pervanadate. For western blotting, a peroxidase-conjugated goat anti-rabbit IgG (H+L) was used as the secondary antibody (1/1000).

      Blocking buffer and concentration: 5% NFDM/TBST.

      Diluting buffer and concentration: 5% NFDM /TBST.

    • Anti-FGFR3 (phospho Y724) antibody [EPR2281(3)] (ab155960)
      Anti-FGFR3 (phospho Y724) antibody [EPR2281(3)] (ab155960)

    Protocols

    • Flow cytometry protocols
    • Immunoprecipitation protocols
    • Immunocytochemistry & immunofluorescence protocols
    • Western blot protocols

    Click here to view the general protocols

    Datasheets and documents

    • SDS download

    • Datasheet download

      Download

    References (10)

    Publishing research using ab155960? Please let us know so that we can cite the reference in this datasheet.

    ab155960 has been referenced in 10 publications.

    • Homer-Bouthiette C  et al. Gait disturbances and muscle dysfunction in fibroblast growth factor 2 knockout mice. Sci Rep 11:11005 (2021). PubMed: 34040128
    • Wu J  et al. Estrogen-Induced Stromal FGF18 Promotes Proliferation and Invasion of Endometrial Carcinoma Cells Through ERK and Akt Signaling. Cancer Manag Res 12:6767-6777 (2020). PubMed: 32801905
    • Lv W  et al. FGF9 alters the Wallerian degeneration process by inhibiting Schwann cell transformation and accelerating macrophage infiltration. Brain Res Bull 152:285-296 (2019). PubMed: 31220553
    • Si J  et al. Shisa3 brakes resistance to EGFR-TKIs in lung adenocarcinoma by suppressing cancer stem cell properties. J Exp Clin Cancer Res 38:481 (2019). PubMed: 31801598
    • Li D  et al. Mg-Zn-Mn alloy extract induces the angiogenesis of human umbilical vein endothelial cells via FGF/FGFR signaling pathway. Biochem Biophys Res Commun 514:618-624 (2019). PubMed: 31076107
    • Datta J  et al. Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398. Mol Cancer Ther 16:614-624 (2017). PubMed: 28255027
    • Takata N  et al. Self-patterning of rostral-caudal neuroectoderm requires dual role of Fgf signaling for localized Wnt antagonism. Nat Commun 8:1339 (2017). PubMed: 29109536
    • Somasundaram R  et al. Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nat Commun 8:607 (2017). PubMed: 28928360
    • Hahn NM  et al. A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157. Clin Cancer Res 23:3003-3011 (2017). PubMed: 27932416
    • Capelletti M  et al. Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma. Clin Cancer Res 20:6551-8 (2014). PubMed: 25294908

    Customer reviews and Q&As

    Show All Reviews Q&A
    Submit a review Submit a question

    1-2 of 2 Abreviews or Q&A

    Western blot abreview for Anti-FGFR3 (phospho Y724) antibody [EPR2281(3)]

    Good
    Abreviews
    Abreviews
    abreview image
    Application
    Western blot
    Sample
    Human Cell lysate - whole cell (lung)
    Gel Running Conditions
    Reduced Denaturing
    Loading amount
    25 µg
    Treatment
    FGF19 (20ng/ml) for 60 minutes
    Specification
    lung
    Blocking step
    Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C
    Read More
    The reviewer received a reward from Abcam’s Loyalty Program in thanks for submitting this Abreview and for helping the scientific community make better-informed decisions.

    Abcam user community

    Verified customer

    Submitted May 25 2017

    Question

    I would like to know how long were the cells treated with parvanadate.

    Read More

    Abcam community

    Verified customer

    Asked on Apr 15 2015

    Answer



    I am happy to confirm that serum starved (overnight) MCF-7 cells were incubated with 1mM pervanadate for 20 minutes at 37℃ to generated the sample we show in the WB image on the datasheet of ab155960.

    Read More

    Anja Hoffmann

    Abcam Scientific Support

    Answered on Apr 15 2015

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com

    Get resources and offers direct to your inbox Sign up
    A-Z by research area
    • Cancer
    • Cardiovascular
    • Cell biology
    • Developmental biology
    • Epigenetics & Nuclear signaling
    • Immunology
    • Metabolism
    • Microbiology
    • Neuroscience
    • Signal transduction
    • Stem cells
    A-Z by product type
    • Primary antibodies
    • Secondary antibodies
    • Biochemicals
    • Isotype controls
    • Flow cytometry multi-color selector
    • Kits
    • Loading controls
    • Lysates
    • Peptides
    • Proteins
    • Slides
    • Tags and cell markers
    • Tools & Reagents
    Help & support
    • Support
    • Make an Inquiry
    • Protocols & troubleshooting
    • Placing an order
    • RabMAb products
    • Biochemical product FAQs
    • Training
    • Browse by Target
    Company
    • Corporate site
    • Investor relations
    • Company news
    • Careers
    • About us
    • Blog
    Events
    • Tradeshows
    • Conferences
    International websites
    • abcam.cn
    • abcam.co.jp

    Join with us

    • LinkedIn
    • facebook
    • Twitter
    • YouTube
    • Terms of sale
    • Website terms of use
    • Cookie policy
    • Privacy policy
    • Legal
    • Modern slavery statement
    © 1998-2022 Abcam plc. All rights reserved.